Proteins for treatment of demyelinating disorders.
Demyelinating disorders (e.g. multiple sclerosis), i.e. conditions characterized by the destruction of the myelin sheaths of the nerves, are severe diseases that require prolonged hospitalization and may lead to death. Thus far, the identity of the molecules mediating the contact between nerve cells during myelination remained elusive. The present technology identifies the proteins responsible for mediating that contact and maintaining myelinated nerves.
• Treatment of neurological disorders which are associated with demyelination
• Diagnosis of neurological damage in a subject
• Building a model of a neurological defect associated with defective cell adhesion and/or myelination, by down-regulating Necl expression in cells
• Treatment of a broad range of neurological disorders
• Enabling the design of more specific and effective drugs to treat demyelination
Myelin sheaths cover many nerve fibers in the central and peripheral nervous system, thus allowing fast and efficient propagation of neural impulses. Disorders that affect myelin interrupt nerve transmission In the present invention it was discovered that Necl proteins are important for mediating contact between cells during myelination in peripheral nerves. One of these Necl proteins, Necl4, has an important role in the development and maintenance of myelinated nerves.